Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From breakthrough shingles vaccines to ViiV Healthcare’s HIV therapies, GSK’s science generates disclosures as complex as its pipeline. If you have ever wondered where the RSV launch costs are buried or how respiratory revenues move the needle, this page brings every document together and answers the questions people actually ask, like “GSK SEC filings explained simply� and “GSK insider trading Form 4 transactions.�
Stock Titan applies AI reading models to each new 20-F, 6-K, or proxy so you can skim instead of sift. Need the GSK quarterly earnings report 10-Q filing or an 8-K material events explained summary? You’ll see real-time alerts, plain-English highlights of vaccine safety data, and side-by-side comparisons of R&D spending. Our platform flags GSK Form 4 insider transactions real-time, traces option grants in the GSK proxy statement executive compensation section, and links each note to the relevant page in the PDF.
Whether you’re tracking patent-cliff timing, modelling Shingrix margins, or verifying GSK executive stock transactions Form 4, you’ll find everything here:
- Annual report 10-K simplified views (alongside the official 20-F)
- AI context for 6-K interim results and GSK earnings report filing analysis
- Instant download of exhibits that disclose trial halts, divestitures, or supply agreements
GSK plc’s 14 July 2025 Form 6-K discloses a series of routine PDMR (Persons Discharging Managerial Responsibilities) transactions covering the period 9-11 July 2025. Executives, senior management and non-executive directors acquired Ordinary Shares on the London Stock Exchange and ADSs on the NYSE through three mechanisms: (1) monthly Share Reward Plan purchases, (2) automatic dividend reinvestment on holdings in Share Reward, Deferred Annual Bonus and Performance Share Plans, and (3) dividend reinvestment on personal ISA or ADS accounts.
Key highlights
- CEO Emma Walmsley executed the largest transactions, adding 16 shares (£14.2073) via the Share Reward Plan, 32 shares (£14.4447) through dividend reinvestment, 4,377 notional shares (£14.5450) in the Deferred Bonus Plan and 9,799.561 shares (£14.5450) in the Performance Share Plan, totalling �14,225 shares at £14.21-14.55.
- CFO Julie Brown purchased 18 physical shares and increased notional holdings by 1,409 shares at £14.5450.
- Other Executive Committee members—including Luke Miels (1,862 shares), David Redfern (1,123 shares) and Tony Wood (1,190 shares)—recorded similar dividend-driven increases.
- Non-executive directors acquired small blocks of ADSs at $38.5396 per ADS; Charles Bancroft bought the largest block (364 ADSs).
- All acquisitions were at market prices set by dividend reinvestment or plan rules; no sales were reported.
The filing signals continued equity alignment by leadership but does not announce any strategic, operational or financial changes. Volumes are modest relative to GSK’s 5 billion-plus share count, suggesting negligible direct market impact.
GSK plc filed a Form 6-K to disclose daily activity under its ongoing share buyback programme. On 11 July 2025 the company repurchased 486,127 ordinary shares (31 ¼ p nominal) on the London Stock Exchange at prices between 1,405.50 p and 1,454.50 p, producing a volume-weighted average price of 1,420.61 p. The shares will be held in treasury.
Including this tranche, GSK has bought back 12,239,897 shares since the non-discretionary agreement with Merrill Lynch International commenced on 4 June 2025. Treasury stock now stands at 230,374,280 shares, representing 5.64 % of total voting rights. The company’s outstanding share count, excluding treasury shares, is 4,085,009,777.
The disclosure also provides granular trade data for regulatory transparency in accordance with the UK FCA’s Disclosure Guidance and Transparency Rules.
GSK plc reported the purchase of 335,358 ordinary shares on 10 July 2025 under its ongoing buy-back programme executed by Merrill Lynch International. Prices ranged from 1,430.50p to 1,462.00p with a volume-weighted average price of 1,449.95p.
Since the programme’s launch on 4 June 2025, GSK has repurchased 11,753,770 shares. Following the latest purchase the company now holds 229,888,153 shares in treasury, representing 5.63 % of total voting rights, leaving 4,085,493,697 shares outstanding (ex-treasury).
The filing consists mainly of the aggregate data above and a detailed schedule of individual trades executed on the London Stock Exchange. No new guidance, financial results or material corporate actions were disclosed.
GSK plc (GSK) filed a Form 6-K detailing activity under its authorised share repurchase programme.
- Date of purchase: 8 July 2025
- Shares bought: 480,940 ordinary shares of 31 ¼ pence each
- Price range: 1,388.50 p � 1,416.50 p; VWAP: 1,405.17 p
- Broker: Merrill Lynch International, acting under a non-discretionary agreement dated 4 June 2025
- Programme progress: Since 4 June 2025 the company has repurchased 10,944,632 shares
- Treasury position: Treasury shares now total 229,079,015, representing 5.61 % of voting rights
- Shares in issue (ex-treasury): 4,086,302,835; this is also the new denominator for FCA DTR 5 calculations
The filing includes a complete schedule of trades executed on the London Stock Exchange (XLON). No trades occurred on CBOE CHIX or BATE on the stated date.
Contact details for media and investor relations representatives are provided. A standard cautionary note reminds investors of forward-looking statement risks.
GSK plc (NYSE/LSE: GSK) filed a Form 6-K disclosing the latest execution under its ongoing £5 billion share repurchase programme. On 4 July 2025 the company, via its broker Merrill Lynch International, bought 484,578 ordinary shares (nominal value 31¼ p) on the London Stock Exchange at prices between 1,388.00 p and 1,415.00 p, for a volume-weighted average price of 1,400.75 p. All shares purchased will be held in treasury.
Since the non-discretionary mandate commenced on 4 June 2025 the company has acquired 9,978,493 ordinary shares. After the latest purchase GSK’s treasury stock rises to 228,112,876 shares, representing 5.58 % of total voting rights. The number of shares outstanding (excluding treasury) stands at 4,087,268,974, which is the new denominator for disclosure under the UK FCA’s DTR 5 rules.
No changes to the size or terms of the authorised buy-back were announced; the filing supplies the customary trading-venue and time-stamp breakdown required under UK regulation.
GSK plc filed a Form 6-K disclosing the latest execution under its ongoing share repurchase programme.
- Shares repurchased: 491,972 ordinary shares on 03 July 2025.
- Price range: 1,380.50 p � 1,411.00 p; VWAP: 1,396.15 p.
- Programme history: Since the non-discretionary agreement with Merrill Lynch International on 04 June 2025, the company has bought back 9,493,915 shares.
- Treasury position: After this purchase GSK holds 227,628,298 shares in treasury, equal to 5.57 % of total voting rights.
- Shares outstanding (ex-treasury): 4,087,741,901.
- The repurchase volume on 03 July represents around 0.012 % of shares in issue, while cumulative June–July purchases equal roughly 0.23 %.
The filing provides the standard denominator for Disclosure Guidance and Transparency Rule (DTR) calculations and lists each individual trade executed on the London Stock Exchange. No other financial, operational or strategic information is included.
FAQ
What is the current stock price of GSK PLC (GSK)?
What is the market cap of GSK PLC (GSK)?
